Filing Details

Accession Number:
0001209191-15-085460
Form Type:
4
Zero Holdings:
No
Publication Time:
2015-12-15 20:27:26
Reporting Period:
2015-12-11
Filing Date:
2015-12-15
Accepted Time:
2015-12-15 20:27:26
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1567514 Intra-Cellular Therapies Inc. ITCI Pharmaceutical Preparations (2834) 364742850
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1585699 Sharon Mates C/O Intra-Cellular Therapies, Inc.
430 East 29Th Street
New York NY 10016
Chairman, President & Ceo Yes Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2015-12-11 25,000 $0.60 1,093,935 No 4 M Direct
Common Stock Acquisiton 2015-12-11 25,000 $1.36 1,118,935 No 4 M Direct
Common Stock Acquisiton 2015-12-11 18,750 $1.50 1,137,685 No 4 M Direct
Common Stock Disposition 2015-12-11 30,046 $53.56 1,107,639 No 4 S Direct
Common Stock Disposition 2015-12-11 19,654 $54.24 1,087,985 No 4 S Direct
Common Stock Disposition 2015-12-11 1,800 $55.08 1,086,185 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 M Direct
No 4 M Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (right to buy) Disposition 2015-12-11 25,000 $0.00 25,000 $0.60
Common Stock Stock Option (right to buy) Disposition 2015-12-11 25,000 $0.00 25,000 $1.36
Common Stock Stock Option (right to buy) Disposition 2015-12-11 18,750 $0.00 18,750 $1.50
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 2015-12-14 No 4 M Direct
0 2016-12-05 No 4 M Direct
18,750 2017-12-12 No 4 M Direct
Footnotes
  1. The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 10, 2015. A majority of the proceeds from these sales will be used to cover the reporting person's tax liability arising from option exercises.
  2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $52.95 to $53.94, inclusive.
  3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $53.97 to $54.96, inclusive.
  4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $54.97 to $55.24, inclusive.
  5. All shares underlying this option have vested.